Literature DB >> 22487680

The p53 isoforms are differentially modified by Mdm2.

Suzanne Camus1, Sergio Ménendez, Kenneth Fernandes, Nelly Kua, Geng Liu, Dimitris P Xirodimas, David P Lane, Jean-Christophe Bourdon.   

Abstract

The discovery that the single p53 gene encodes several different p53 protein isoforms has initiated a flurry of research into the function and regulation of these novel p53 proteins. Full-length p53 protein level is primarily regulated by the E3-ligase Mdm2, which promotes p53 ubiquitination and degradation. Here, we report that all of the novel p53 isoforms are ubiquitinated and degraded to varying degrees in an Mdm2-dependent and -independent manner, and that high-risk human papillomavirus can degrade some but not all of the novel isoforms, demonstrating that full-length p53 and the p53 isoforms are differentially regulated. In addition, we provide the first evidence that Mdm2 promotes the NEDDylation of p53β. Altogether, our data indicates that Mdm2 can distinguish between the p53 isoforms and modify them differently.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487680      PMCID: PMC3341231          DOI: 10.4161/cc.20119

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  54 in total

1.  Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.

Authors:  Virginie Marcel; Stéphane Perrier; Mustapha Aoubala; Sylvain Ageorges; Michael J Groves; Alexandra Diot; Kenneth Fernandes; Sudhir Tauro; Jean-Christophe Bourdon
Journal:  FEBS Lett       Date:  2010-10-13       Impact factor: 4.124

2.  Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.

Authors:  Steffen Schubert; Arnold Grünweller; Volker A Erdmann; Jens Kurreck
Journal:  J Mol Biol       Date:  2005-05-13       Impact factor: 5.469

3.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.

Authors:  M G Mateu; A R Fersht
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

4.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation.

Authors:  Kurt A Krummel; Crystal J Lee; Franck Toledo; Geoffrey M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

5.  p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.

Authors:  M Aoubala; F Murray-Zmijewski; M P Khoury; K Fernandes; S Perrier; H Bernard; A-C Prats; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2010-08-06       Impact factor: 15.828

6.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.

Authors:  M Kaghad; H Bonnet; A Yang; L Creancier; J C Biscan; A Valent; A Minty; P Chalon; J M Lelias; X Dumont; P Ferrara; F McKeon; D Caput
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

8.  The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.

Authors:  Harumi Shimizu; Lindsay R Burch; Amanda J Smith; David Dornan; Maura Wallace; Kathryn L Ball; Ted R Hupp
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

9.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

10.  The human tumour suppressor gene p53 is alternatively spliced in normal cells.

Authors:  J M Flaman; F Waridel; A Estreicher; A Vannier; J M Limacher; D Gilbert; R Iggo; T Frebourg
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

View more
  15 in total

1.  Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.

Authors:  V Marcel; K Fernandes; O Terrier; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2014-06-13       Impact factor: 15.828

2.  Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms.

Authors:  Jessica Beck; Casmir Turnquist; Izumi Horikawa; Curtis Harris
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

3.  The Balance between p53 Isoforms Modulates the Efficiency of HIV-1 Infection in Macrophages.

Authors:  Yann Breton; Corinne Barat; Michel J Tremblay
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

4.  A Novel Role of SMG1 in Cholesterol Homeostasis That Depends Partially on p53 Alternative Splicing.

Authors:  Muyang Li; Fredrick Philantrope; Alexandra Diot; Jean-Christophe Bourdon; Patricia Thompson
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

5.  Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Authors:  Wansheng Ji; Na Zhang; Hongmei Zhang; Jingrong Ma; Hua Zhong; Jianxin Jiao; Zhixing Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.

Authors:  M New; H Olzscha; G Liu; O Khan; L Stimson; J McGouran; D Kerr; A Coutts; B Kessler; M Middleton; N B La Thangue
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

7.  Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.

Authors:  Elisabeth Silden; Sigrun M Hjelle; Line Wergeland; André Sulen; Vibeke Andresen; Jean-Christophe Bourdon; David R Micklem; Emmet McCormack; Bjørn Tore Gjertsen
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

Review 8.  Uncovering the role of p53 splice variants in human malignancy: a clinical perspective.

Authors:  Sylvanie Surget; Marie P Khoury; Jean-Christophe Bourdon
Journal:  Onco Targets Ther       Date:  2013-12-19       Impact factor: 4.147

9.  A multi-split mapping algorithm for circular RNA, splicing, trans-splicing and fusion detection.

Authors:  Steve Hoffmann; Christian Otto; Gero Doose; Andrea Tanzer; David Langenberger; Sabina Christ; Manfred Kunz; Lesca M Holdt; Daniel Teupser; Jörg Hackermüller; Peter F Stadler
Journal:  Genome Biol       Date:  2014-02-10       Impact factor: 13.583

10.  Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.

Authors:  Alan S Coates; Ewan K A Millar; Sandra A O'Toole; Timothy J Molloy; Giuseppe Viale; Aron Goldhirsch; Meredith M Regan; Richard D Gelber; Zhuoxin Sun; Monica Castiglione-Gertsch; Barry Gusterson; Elizabeth A Musgrove; Robert L Sutherland
Journal:  Breast Cancer Res       Date:  2012-11-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.